Your browser doesn't support javascript.
loading
Bis-cyclopropane analog of disorazole C1 is a microtubule-destabilizing agent active in ABCB1-overexpressing human colon cancer cells.
Wu, Shaoyu; Guo, Zhijian; Hopkins, Chad D; Wei, Ning; Chu, Edward; Wipf, Peter; Schmitz, John C.
Afiliación
  • Wu S; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA.
  • Guo Z; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  • Hopkins CD; Department of Chemistry, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, China.
  • Wei N; Department of Nephrology, NanFang Hospital, Southern Medical University, Guangzhou 510515, China.
  • Chu E; Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA.
  • Wipf P; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA.
  • Schmitz JC; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Oncotarget ; 6(38): 40866-79, 2015 Dec 01.
Article en En | MEDLINE | ID: mdl-26506423
ABSTRACT
The novel, chemically stabilized disorazole analog, (-)-CP2-disorazole C1 (1) displayed potent anti-proliferative activity against a broad-spectrum of human colorectal cancer cells. HCT15 and H630R1 cell lines expressing high basal levels of the ABCB1 protein, known to cause multi-drug resistance, were also sensitive to growth inhibition by 1 but were resistant to both vincristine and docetaxel, two commonly used microtubule inhibitors. Compound 1 exhibited strong inhibition of tubulin polymerization at a level comparable to vincristine. In addition, treatment with 1 resulted in decreased protein levels of ß-tubulin but not α-tubulin. An analysis of cellular proteins known to interact with microtubules showed that 1 caused decreased expression of c-Myc, APC, Rb, and additional key cellular signaling pathways in CRC cells. Treatment with compound 1 also resulted in G2/M cell cycle arrest and induction of apoptosis, but not senescence. Furthermore, endothelial spheroid sprouting assays demonstrated that 1 suppressed angiogenesis and can, therefore, potentially prevent cancer cells from spreading and metastasizing. Taken together, these findings suggest that the microtubule disruptor 1 may be a potential drug candidate for the treatment of mCRC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oxazoles / Neoplasias del Colon / Resistencia a Múltiples Medicamentos / Macrólidos / Microtúbulos / Antineoplásicos Límite: Humans Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oxazoles / Neoplasias del Colon / Resistencia a Múltiples Medicamentos / Macrólidos / Microtúbulos / Antineoplásicos Límite: Humans Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos